Treatment of ulcerative colitis with oral mesalamine: Advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention

Reviews in Gastroenterological Disorders

Volumn 6, Issue 2, 2006, Pages 97-105

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

5 aminosalicylate; Balsalazide; Controlled release mesalamine; Delayed release mesalamine; Mesalamine pellets; Multi Matrix System mesalamine; Olsalazine; Sulfasalazine; Ulcerative colitis

Indexed keywords

BALSALAZIDE; EN TABS; MESALAZINE; MESAVANCE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; SPD 476;

ABDOMINAL PAIN; AGRANULOCYTOSIS; APLASTIC ANEMIA; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED RELEASE FORMULATION; CYANOSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EPIDERMOLYSIS; EPIGASTRIC PAIN; FOLIC ACID DEFICIENCY; HEADACHE; HEPATITIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LEUKOPENIA; LUNG DISEASE; LUNG TOXICITY; MALE INFERTILITY; NAUSEA AND VOMITING; PANCREATITIS; PATIENT COMPLIANCE; PERICARDITIS; REMISSION; RETICULOSIS; REVIEW; RISK REDUCTION; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; CHEMOPREVENTION; CLINICAL TRIALS; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MESALAMINE; PATIENT COMPLIANCE; PHENYLHYDRAZINES; REMISSION INDUCTION; SULFASALAZINE;

EID: 33744817063     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Das K, Eastwood M, McManus J, Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. II. The relationship between metabolites and the progress of the disease studied in out-patients. Gut. 1973;14:637-641.
2. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181: 555-562.
3. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2:892-895.
4. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42.
5. Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther. 2003;17:1163-1169.
6. Baron JH, Connell AM, Lennard-Jones JE, Jones FA. Sulfasalazine and salicylazosulphaadimidine in ulcerative colitis. Lancet. 1962;1:1094-1096.
7. Dick AP, Grayson AP, Carpenter RG, Petrie A. A controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut. 1964;5:437-442.
8. Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet. 1965;1:185-188.
9. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut. 1973;14:923-926.
10. Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980; 21:232-240.
11. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987;93:1255-1262.
12. Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol. 1990;85:562-566.
13. Hanauer SB, Barish C, Pambianco D, et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology, 1996;110:A921.
14. Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut. 1989;30:1354-1361.
15. Hetzel DJ, Shearman DJ, Labrooy J, et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scand J Gastroenterol Suppl. 1988;148:61-69.
16. Selby WS, Barr GD, Ireland A, et al. Olsalazine in active ulcerative colitis. Br Medl J Clin Res Ed. 1985;291:1373-1375.
17. Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology. 1988;95:975-981.
18. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986;90:1024-1030.
19. Wright JP, O'Keefe EA, Cuming L, Jaskiewicz K. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci. 1993;38:1837-1842.
20. Levine DS, Riff DS, Pruitt R, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97:1398-1407.
21. Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology. 1998;114:15-22.
22. Giaffer MH, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther. 1992; 6:479-485.
23. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
24. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991;115:350-355.
25. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.
26. Anonymous. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group [see comment]. Ann Intern Med 1996;124:204-211.
27. Hanauer S, Schwartz J, Robinson M., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993; 88:1188-1197.
28. Miner P, Hanauer S, Robinson M., et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995;40:296-304.
29. Kruis W, Bar-Meir S, Feher J, et al., for the International Salofalk Pellets Study Group. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol. 2003;1:36-43.
30. Marakhouski Y, Fixa B, Holoman J, et al., for the International Salofalk Study Group. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. [Erratum appears in Aliment Pharmacol Ther. 2005;21:793.] Aliment Pharmacol Ther. 2005;21:133-140.
31. Lichtenstein G, Kamm M, Sandborn W, et al. SPD476 is a novel, once-daily, effective and well-tolerated 5-ASA formulation for the induction of remission of mild-to-moderate ulcerative colitis: a phase III study. Am J Gastroenterol. 2005;100:S291 Abstract.
32. Kamm M, Sandborn W, Gassull M, et al. Comparison of the efficacy and safety of SPD476, a novel, once-daily formulation of mesalamine, and Asacol with placebo for the induction of remission of mild-moderate ulcerative colitis: a phase III study. Am J Gastroenterol. 2005;100: S291 Abstract
33. Prescribing information for Pentasa (mesalamine). Package insert; 2005.
34. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993;118:540-549.
35. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis. 1997;3:65-78.
36. Van Deventer SJH, Hommes DW, Roskam-Mul MDM, et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology. 2001;120:A454.
37. Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973; 289:491-495.
38. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci. 1983;28:833-842.
39. Loftus EV, Kane SV, Bjorkman D. Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19:179-189.
40. Brouillard M, Gheerbrant JD, Gheysens Y, et al. Chronic interstitial nephritis and mesalazine: 3 new cases? Gastroenterol Clin Biol. 1998;22: 724-726.
41. Calvino J, Romero R, Pintos E, et al. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol. 1998;49: 265-267.
42. Izzedine H, Simon J, Piette AM, et al. Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology. 2002;123:1436-1440.
43. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut. 1992;33:1348-1352.
44. Schreiber S, Hamling J, Zehnter E, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut. 1997;40:761-766.
45. Fraser JS, Muller AF, Smith DJ, et al. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther. 2001;15:1131-1137.
46. Mahmud N, O'Toole D, O'Hare N, et al. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther. 2002;16:207-215.
47. Hanauer SB, Verst-Brasch C, Regalli G. Renal safety of long-term mesalamine therapy in inflammatory bowel disease (IBD). Gastroenterology. 1997;112:A991.
48. Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther. 1996;10:949-956.
49. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
50. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114: 39-43.
51. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily dosing versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170-173.
52. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8:1179-1183.
53. Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology. 1997;112:29-32.
54. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001;44:77-85.
55. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107:117-120.
56. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14:145-153.
57. Rubin DT, Djordjevic A, Huo D, et al. Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer (CRC) in ulcerative colitis (UC). Gastroenterology. 2003;124:A-36.
58. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
59. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.
60. Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? [see comment]. Am J Gastroenterol. 2003;98:2784-2788.
61. Velayos FS, Loftus EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. In Press.
62. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.